Videos

Opthea Eye Phase IIB Trial in 2017

By Mario Admin | November 21, 2016

Opthea, a public company listed on the Australian Stock Exchange, is developing OPT-302, a novel therapy for wet age-related macular degeneration (AMD). The company’s lead…

Read More

Z Lens: Using Zonules for Accommodation/Disaccommodation

By Jackie Wengrod | November 21, 2016

New to the anterior segment arena, Z Lens was founded by Paul Beer, MD, and Edward Eveleth. Dr. Beer has more than 28 years’ experience…

Read More
Avedro

Avedro Optimistic on Future of CXL

By Jackie Wengrod | November 21, 2016

Avedro’s chief medical officer, Rajesh K. Rajpal, MD, said 2016 marked the first US Food and Drug Administration approval of a collagen cross-linking (CXL) device,…

Read More
apellis-pharmaceuticals

Apellis Eyeing 2017 Release of Phase II Results

By Mario Admin | November 17, 2016

Appellis CEO Cedric Francois delivered an update on his company’s fully enrolled Phase III Filly trial of APL-2, a peptide targeting the C3 inhibitor in…

Read More

PanOptica Offers “Something Completely Different”

By Mario Admin | November 17, 2016

Paul Chaney, president and CEO, PanOptica, brought the OIS@AAO crowd up to speed on the progress of PAN-90806, a topical eyedrop for the treatment of…

Read More

Ohr Set to Begin Phase III Trials for Wet AMD

By Mario Admin | November 17, 2016

Jason Slakter, CEO, Ohr Pharmaceutical, told OIS@AAO attendees that the company is enrolling patients in a Phase III clinical trial to test the efficacy of…

Read More

SalutarisMD

By Mario Admin | November 16, 2016

Salutaris Medical Devices, Inc. (SalutarisMD®), is a clinical-stage company anticipating first sales revenue in early 2017. SalutarisMD is developing a minimally invasive treatment for Wet…

Read More

Inotek “Transforming Glaucoma Treatments”

By Mario Admin | November 15, 2016

CHICAGO—Inotek is committed to “transforming glaucoma treatments,” David Southwell, president and CEO, said here during the Ophthalmology Innovation Summit. Glaucoma is a $5.6 billion worldwide…

Read More

QLT: Using Oral Products to Treat Retinal Disorders

By Mario Admin | November 15, 2016

CHICAGO—QLT, a biotechnology company, is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases, said David Saperstein, MD, chief…

Read More
graybug-vision

Graybug Builds Team, Advances Pipeline

By Mario Admin | November 15, 2016

Jeffrey Cleland, president and CEO, Graybug Vision, reports progress on its two treatments for wet age-related macular degeneration (wet AMD) and glaucoma. The company is…

Read More

Ocular Therapeutix’s Depot Programs Move Forward

By Mario Admin | November 15, 2016

Ocular Therapeutix entered into a collaboration with Regeneron Pharmaceuticals to develop a sustained-release formulation of Eylea (aflibercept), Ocular Therapeutix president, CEO, and chairman Amar Sawhney,…

Read More

Aerpio’s Unique Approach to Activating Tie2

By Mario Admin | November 15, 2016

Joseph Gardner, president and CEO of Aerpio Therapeutics, acknowledged that his company is not alone in developing Tie2-activating agents to treat retinal disease, but at…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.